Evommune, Inc.
corporate_fare Company Profile
Evommune, Inc. (NYSE:EVMN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for EVMN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for EVMN spans 8-K, 424B3, 10-Q, DEF 14A.
Recent high-impact activity:
- Evommune's EVO301 Shows 55% EASI Reduction in Phase 2a Atopic Dermatitis Data
- Evommune to Present Positive Phase 2a EVO301 Data at EADV; Phase 2b Set for Mid-2027
- Evommune's Updated Corporate Presentation Highlights Positive EVO301 Phase 2a Data and Extended Cash Runway to 2029
- Evommune Halts EVO756 in Atopic Dermatitis After Phase 2b Failure; Cash Runway Extended to 2029
- Evommune Halts EVO756 in Atopic Dermatitis After Phase 2b Failure; Pivots to Migraine
Financial Snapshot
Short Interest & Short Volume
3.42 days to coverFINRA reported short interest of 3,533,042 shares in EVMN as of the October 15, 2026 settlement, a 22.2% increase from the prior period — about 3.4 days to cover at its recent average daily volume. On November 2, 2026, 54.1% of EVMN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.